Search
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Linifanib
go.drugbank.com/drugs/DB06080InvestigationalLinifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels
ICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIt is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … ICA-105665 is a novel small molecule compound for the treatment of epilepsy.
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
RP01
go.drugbank.com/drugs/DB05751ExperimentalIt could offer benefit to millions of asthma and allergy patients. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.
Afabicin
go.drugbank.com/drugs/DB15268InvestigationalAfabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus
Lulizumab pegol
go.drugbank.com/drugs/DB15441InvestigationalLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalIt targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin. … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.
Pinatuzumab vedotin
go.drugbank.com/drugs/DB15432InvestigationalPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or … Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
R450
go.drugbank.com/drugs/DB05469ExperimentalIt is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.